Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.03
-0.9200-5.13%
Volume:584.58K
Turnover:10.12M
Market Cap:13.59B
PE:-15.24
High:17.64
Open:17.61
Low:17.01
Close:17.95
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:154.32M
Volume Ratio:2.07
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.57
PE(LYR):-11.79

Loading ...

Vehicle production drops in first half of year

cityam
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

TIPRANKS
·
Jul 29

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

TIPRANKS
·
Jul 27

Summit Therapeutics (SMMT) Updates Ivonescimab Progress, Is The 52% Undervalued View Convincing?

Simply Wall St.
·
Jul 27

Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations

TIPRANKS
·
Jul 25

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Benzinga Earnings
·
Jul 24

U.S. Stocks on the Move-booz Allen Hamilton, Sensient, Amkor

Reuters
·
Jul 24

U.S. Stocks on the Move-tenet Healthcare, Intel, Verizon

Reuters
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Summit Therapeutics (SMMT) and Progyny (PGNY)

TIPRANKS
·
Jul 24

Summit Therapeutics Falls After Share Sale Plans, Q2 Report

Reuters
·
Jul 24

Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Jul 24

Stock Track | Summit Therapeutics PLC Plunges 5.54% Intraday on Widening Non-GAAP Loss and $380 Million Stock Offering Plan

Stock Track
·
Jul 24

Summit Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 24

Summit Therapeutics Launches At-the-market Equity Program for up to $380 Million

Reuters
·
Jul 24

Stock Track | Summit Therapeutics Plunges 6% After-Hours as Non-GAAP Loss Widens on Surging Ivonescimab Development Costs

Stock Track
·
Jul 24

Summit Therapeutics says will need to raise additional capital

TIPRANKS
·
Jul 24

Summit Therapeutics - to Offer and Sell Common Stock up to $380 Mln Aggregate Through Sales Agent - SEC Filing

THOMSON REUTERS
·
Jul 24

Summit Therapeutics Q2 FY26 Net Loss Narrows to $215.7 Million

Reuters
·
Jul 24

Summit Therapeutics Q2 Net Income USD -215.7 Million

Reuters
·
Jul 24

Summit Therapeutics Q2 EPS USD -0.28

THOMSON REUTERS
·
Jul 24